Stock analysis of Eli Lilly (LLY)
Eli Lilly and Company (NYSE: LLY) was founded almost 150 years ago in 1876 by Colonel Eli Lilly and it is one of the leaders in the healthcare industry. The company has its HQ in Indianapolis, Indiana, has more than 44,000 employees and its products are marketed in approximately 105 countries, as can be seen in their website. They have a growing portfolio of medicines in key areas, which are: Alzheimer's Pain; Cancer; Immunology; Diabetes; Obesity. These last two categories are the main reason why the stock is rallying lately, thanks to its new obesity and diabetes drugs Mounjaro and Zepbound. Another factor that is pushing the stock price up, is their new Alzheimer’s drug, which is in late-stage trials. In 2024, the company had an impressive performance of +45.82%…